End-Stage Renal Disease (ESRD)NCT07303179
Exercise Rehabilitation for Functional Impairment in Maintenance Hemodialysis Patients
A study testing Exercise Rehabilitation Therapy (ERT) in people with End-Stage Renal Disease (ESRD) and Maintenance Hemodialysis (MHD), run by The First People's Hospital of Yunnan at 1 site in China.
Trial summary
Maintenance hemodialysis (MHD) is the main treatment for patients with end-stage renal disease (ESRD). Although dialysis prolongs survival, many patients experience reduced physical function, poor quality of life, and higher risks of hospitalization and death. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- End-Stage Renal Disease (ESRD), Maintenance Hemodialysis (MHD)
- What is being tested?
- Exercise Rehabilitation Therapy (ERT)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2025to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- On maintenance hemodialysis for ≥3 months.
- Age 18-74 years.
- Receiving adequate standard medical management.
- Hemodialysis frequency: 3 times per week.
- Kt/V > 1.2.
Who cannot join
- New York Heart Association (NYHA) class IV heart failure.
- Recent uncontrolled unstable angina.
- Severe peripheral arterial disease or musculoskeletal disorders.
- Walking distance <200 meters.
- Resting oxygen saturation <90%.
- Amputation or other conditions precluding exercise.
Trial locations and contacts
1 site in 1 country.
China1 site
The First People's Hospital of Yunnan Province
Kunming, Yunnan, 650032
About this study
Official title: A Multicenter, Randomized Controlled Study on the Evaluation of Functional Impairment and the Promotion of Exercise Rehabilitation Standards in Maintenance Hemodialysis (MHD) Patients
Maintenance hemodialysis (MHD) is the main treatment for patients with end-stage renal disease (ESRD). Although dialysis prolongs survival, many patients experience reduced physical function, poor quality of life, and higher risks of hospitalization and death. Lack of exercise often leads to muscle weakness and disability, further burdening patients, families, and healthcare systems.
Rehabilitation medicine has shown promise in improving outcomes in patients with chronic kidney disease. Chinese experts have developed the "Standards for Rehabilitation Services in CKD Patients," which outline goals, procedures, and safety measures for exercise interventions. Based on these Standards, this study will evaluate the effects of structured exercise rehabilitation techniques (ERT) during routine dialysis.
Read more
This multicenter, randomized controlled trial will enroll 800 patients from 15 dialysis centers in China, including 40 patients at The First People's Hospital of Yunnan Province. Eligible patients will be randomly assigned to an intervention group (dialysis plus ERT) or a control group (dialysis only). ERT includes warm-up, core resistance and cycling exercises, and relaxation, performed 3 times per week for 20-60 minutes per session over 2 years.
The study will assess whether ERT can improve muscle strength, walking distance, psychological health, nutritional and cognitive status, and overall quality of life. Hospitalization and mortality will also be recorded as clinical outcomes. Results will provide scientific evidence for the feasibility, safety, and effectiveness of promoting standardized exercise rehabilitation in MHD patients.
- Being tested
- Exercise Rehabilitation Therapy (ERT)
- Keywords
- Exercise Rehabilitation, Maintenance Hemodialysis, Physical Function
- Medical subject headings
- Kidney Failure, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise Rehabilitation Therapy (ERT)Behavioural
Also called Exercise Rehabilitation Therapy, Exercise Training Program
The intervention follows the "Standards for Rehabilitation Services in CKD Patients" and applies structured exercise rehabilitation therapy (ERT) in addition to routine maintenance hemodialysis. The ERT program includes three phases:
Warm-up exercises (e.g., stretching, limb flexion/extension, leg raises),
Core exercises (e.g., upper-limb resistance training, bedside cycling),
Relaxation exercises (e.g., whole-body stretching).
Each session will last 20-60 minutes, three times per week, for a total of two years.
| Study group | Role | What they receive |
|---|---|---|
| Exercise Rehabilitation Group | Experimental | This arm will follow the "Standards for Rehabilitation Services in CKD Patients" and receive structured exercise rehabilitation therapy (ERT) in addition to routine hemodialysis. The intervention includes three phases:
Warm-up exercises (e.g., stretching, limb flexion/extension, leg raises),
Core exercises (e.g., upper-limb resistance training, bedside cycling),
Relaxation exercises (e.g., whole-body stretching).
Each session will last 20-60 minutes, three times per week, for a total duration of two years. All sessions will be supervised by trained healthcare staff, and exercise prescriptions will be individualized according to patient condition to ensure safety and feasibility. Receives: Behavioral: Exercise Rehabilitation Therapy (ERT) |
| Control Group | No intervention | Participants in this group will receive routine maintenance hemodialysis only, without any additional exercise intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in 6-minute walk distance (6MWD)
Functional capacity will be assessed using the 6-minute walk test (6MWT) at baseline and every 6 months. The change in walking distance reflects improvement in functional impairment and exercise tolerance among maintenance hemodialysis (MHD) patients receiving standardized exercise rehabilitation therapy (ERT). Unit of Measure: Meters (m).
Measured: From enrollment until 2 years after the end of intervention.
Incidence of hospitalization due to cardiovascular events
Hospitalizations caused by cardiovascular events will be recorded, including acute myocardial infarction, other acute coronary syndromes, congestive heart failure requiring hospitalization, and severe arrhythmias (e.g., complete atrioventricular block, cardiac arrest). Data will be used to assess whether ERT reduces cardiovascular morbidity. Incidence will be expressed as the proportion of participants experiencing at least one event during the follow-up period.
Measured: From enrollment until 2 years after the end of intervention.
Incidence of cerebrovascular events
The occurrence of cerebrovascular events, including intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke (cardioembolic or other etiologies), will be documented and compared between the ERT and control groups. Incidence will be expressed as the proportion of participants experiencing at least one event during the follow-up period.
Measured: From enrollment until 2 years after the end of intervention.
All-cause mortality
All-cause mortality will be monitored throughout the study to evaluate the long-term safety and prognostic impact of standardized exercise rehabilitation therapy in MHD patients. All-cause mortality will be expressed as the proportion of participants who die from any cause during the follow-up period.
Measured: From enrollment until 2 years after the end of intervention.
Secondary outcomes (20)
Change in handgrip strength
Handgrip strength will be assessed using a calibrated handgrip dynamometer. Measurements will be performed at baseline and every 6 months during the study period. The change in handgrip strength will reflect improvements in upper limb muscle strength among maintenance hemodialysis (MHD) patients receiving standardized exercise rehabilitation therapy (ERT).
Unit of Measure: Kilograms (kg)
Measured: From enrollment until 2 years after the end of intervention.
Change in lower limb muscle strength assessed by Five Times Sit-to-Stand Test (5STS)
Lower limb muscle strength will be assessed using the Five Times Sit-to-Stand Test (5STS). Participants will be seated on a standard armless chair (43 cm in height) with feet flat on the floor, arms crossed over the chest, and the back not supported by the chair. Upon the verbal command "start," participants will be instructed to stand up fully and sit down five times as quickly as possible. Timing will begin at the start command and stop when the participant completes the fifth stand. The time required to complete five repetitions will be recorded.
Assessments will be performed at baseline and every 6 months during the study period. Changes in 5STS performance will reflect improvements in lower limb muscle function among maintenance hemodialysis patients receiving standardized exercise rehabilitation therapy (ERT). Unit of Measure: Seconds (s)
Measured: From enrollment until 2 years after the end of intervention.
Change in depressive symptoms assessed by the Self-Rating Depression Scale (SDS)
Depressive symptoms will be evaluated using the Self-Rating Depression Scale (SDS), a validated self-report instrument comprising 20 items rated on a 4-point Likert scale. The total raw score is converted to a standard score, with higher scores indicating more severe depressive symptoms. Assessments will be performed at baseline and every 6 months. Changes in SDS scores will reflect the impact of exercise rehabilitation therapy (ERT) on depression among maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (SDS standard score range: 25-100).
Measured: From enrollment until 2 years after the end of intervention.
Change in anxiety level assessed by the Self-Rating Anxiety Scale (SAS)
Anxiety symptoms will be assessed using the Self-Rating Anxiety Scale (SAS), a validated self-administered questionnaire consisting of 20 items. Each item is rated on a 4-point Likert scale. The total raw score is converted to a standard score, with higher scores indicating more severe anxiety symptoms. Assessments will be conducted at baseline and every 6 months during the study period. Changes in SAS scores will be used to evaluate the effect of exercise rehabilitation therapy (ERT) on anxiety levels in maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (SAS standard score range: 25-100).
Measured: From enrollment until 2 years after the end of intervention.
Change in body mass index (BMI)
Body mass index (BMI) will be calculated as body weight divided by the square of height (kg/m²). Measurements will be obtained at baseline and every 6 months. Changes in BMI will be used to evaluate the impact of exercise rehabilitation therapy (ERT) on body composition and nutritional status in maintenance hemodialysis (MHD) patients. Unit of Measure: Kilograms per square meter (kg/m²).
Measured: From enrollment until 2 years after the end of intervention.
Change in cognitive function assessed by the Montreal Cognitive Assessment (MoCA)
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA) at baseline and every 6 months. The MoCA is a 30-point cognitive screening tool evaluating domains including attention, memory, language, and executive function, where higher scores indicate better cognitive performance. Changes in MoCA scores will be used to assess the effect of exercise rehabilitation therapy (ERT) on cognitive function in maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (MoCA score range: 0-30).
Measured: From enrollment until 2 years after the end of intervention.
Change in self-management ability assessed by the Hemodialysis Self-Management Scale
Self-management ability will be assessed using the Hemodialysis Self-Management Scale, a 20-item patient-reported questionnaire designed to evaluate self-management behaviors in patients undergoing maintenance hemodialysis. The scale assesses domains such as treatment adherence, dietary and fluid management, symptom monitoring, and health-related behaviors. Assessments will be conducted at baseline and every 6 months during the study period. Changes in self-management scores will be used to evaluate the effect of exercise rehabilitation therapy (ERT) on self-management ability in maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (total score; range: 0-20)
Measured: From enrollment until 2 years after the end of intervention.
Change in urea reduction ratio (URR)
Urea reduction ratio (URR) will be calculated based on pre- and post-dialysis blood urea levels at baseline and every 3 months to evaluate dialysis adequacy. Unit of Measure: Percent (%). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in single-pool Kt/V for urea
Single-pool Kt/V for urea will be calculated at baseline and every 3 months using pre- and post-dialysis blood urea concentrations to assess dialysis adequacy in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Dimensionless. Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in hemoglobin concentration
Hemoglobin concentration will be measured at baseline and every 3 months to evaluate changes in anemia status in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Grams per liter (g/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in serum ferritin
Serum ferritin levels will be measured at baseline and every 3 months to assess changes in iron stores in MHD patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Nanograms per milliliter (ng/mL). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in transferrin saturation (TSAT)
Transferrin saturation (TSAT) will be calculated at baseline and every 3 months to evaluate iron utilization in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Percent (%). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in serum calcium
Serum calcium levels will be measured at baseline and every 3 months to assess changes in mineral metabolism in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in serum phosphate
Serum phosphate concentrations will be measured at baseline and every 3 months to evaluate changes in mineral metabolism in maintenance hemodialysis (MHD) patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in intact parathyroid hormone (iPTH)
Serum intact parathyroid hormone (iPTH) levels will be measured at baseline and every 3 months to assess changes in parathyroid function and mineral bone disorder status in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Picograms per milliliter (pg/mL). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in C-reactive protein (CRP)
Serum C-reactive protein (CRP) levels will be measured at baseline and every 3 months to assess changes in systemic inflammation associated with exercise rehabilitation therapy (ERT) in maintenance hemodialysis (MHD) patients. Unit of Measure: Milligrams per liter (mg/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in serum albumin
Serum albumin concentration will be measured at baseline and every 3 months to evaluate changes in nutritional status in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Grams per liter (g/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in prealbumin
Serum prealbumin levels will be assessed at baseline and every 3 months to evaluate short-term changes in nutritional status in maintenance hemodialysis (MHD) patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Milligrams per liter (mg/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in triglycerides
Serum triglyceride levels will be measured at baseline and every 3 months to assess changes in lipid metabolism in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Change in total cholesterol
Total serum cholesterol levels will be measured at baseline and every 3 months to evaluate changes in lipid profile in maintenance hemodialysis (MHD) patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.
Measured: From enrollment until 2 years after the end of intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start1 Jun 2025
- Primary completion1 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for End-Stage Renal Disease (ESRD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- The First People's Hospital of Yunnan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qinyuan Deng, The First People's Hospital of Yunnan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07303179
- Sponsor's protocol ID
- KFKT-1023-005
- Status last verified
- Feb 2026
- First submitted
- 25 Sep 2025
- Last updated
- 10 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized Controlled Study on the Evaluation of Functional Impairment and the Promotion of Exercise Rehabilitation Standards in Maintenance Hemodialysis (MHD) Patients
- ClinicalTrials.gov ID
- NCT07303179
- Acronym / sponsor ID
- KFKT-1023-005
- Keywords
- Exercise Rehabilitation, Maintenance Hemodialysis, Physical Function
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (actual)
- Lead sponsor
- The First People's Hospital of YunnanUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Maintenance hemodialysis (MHD) is the main treatment for patients with end-stage renal disease (ESRD). Although dialysis prolongs survival, many patients experience reduced physical function, poor quality of life, and higher risks of hospitalization and death. Lack of exercise often leads to muscle weakness and disability, further burdening patients, families, and healthcare systems.
Rehabilitation medicine has shown promise in improving outcomes in patients with chronic kidney disease. Chinese experts have developed the "Standards for Rehabilitation Services in CKD Patients," which outline goals, procedures, and safety measures for exercise interventions. Based on these Standards, this study will evaluate the effects of structured exercise rehabilitation techniques (ERT) during routine dialysis.
This multicenter, randomized controlled trial will enroll 800 patients from 15 dialysis centers in China, including 40 patients at The First People's Hospital of Yunnan Province. Eligible patients will be randomly assigned to an intervention group (dialysis plus ERT) or a control group (dialysis only). ERT includes warm-up, core resistance and cycling exercises, and relaxation, performed 3 times per week for 20-60 minutes per session over 2 years.
The study will assess whether ERT can improve muscle strength, walking distance, psychological health, nutritional and cognitive status, and overall quality of life. Hospitalization and mortality will also be recorded as clinical outcomes. Results will provide scientific evidence for the feasibility, safety, and effectiveness of promoting standardized exercise rehabilitation in MHD patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exercise Rehabilitation Group | Experimental | Behavioral: Exercise Rehabilitation Therapy (ERT)This arm will follow the "Standards for Rehabilitation Services in CKD Patients" and receive structured exercise rehabilitation therapy (ERT) in addition to routine hemodialysis. The intervention includes three phases: Warm-up exercises (e.g., stretching, limb flexion/extension, leg raises), Core exercises (e.g., upper-limb resistance training, bedside cycling), Relaxation exercises (e.g., whole-body stretching). Each session will last 20-60 minutes, three times per week, for a total duration of two years. All sessions will be supervised by trained healthcare staff, and exercise prescriptions will be individualized according to patient condition to ensure safety and feasibility. |
| Control Group | No intervention | –Participants in this group will receive routine maintenance hemodialysis only, without any additional exercise intervention. |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- On maintenance hemodialysis for ≥3 months.
- Age 18-74 years.
- Receiving adequate standard medical management.
- Hemodialysis frequency: 3 times per week.
- Kt/V > 1.2.
Key exclusion criteria (6 listed)
- New York Heart Association (NYHA) class IV heart failure.
- Recent uncontrolled unstable angina.
- Severe peripheral arterial disease or musculoskeletal disorders.
- Walking distance <200 meters.
- Resting oxygen saturation <90%.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise Rehabilitation Therapy (ERT)Also: Exercise Rehabilitation Therapy, Exercise Training ProgramThe intervention follows the "Standards for Rehabilitation Services in CKD Patients" and applies structured exercise rehabilitation therapy (ERT) in addition to routine maintenance hemodialysis. The ERT program includes three phases: Warm-up exercises (e.g., stretching, limb flexion/extension, leg raises), Core exercises (e.g., upper-limb resistance training, bedside cycling), Relaxation exercises (e.g., whole-body stretching). Each session will last 20-60 minutes, three times per week, for a total of two years. | Behavioural | Exercise Rehabilitation Group |
Primary outcome
Change in 6-minute walk distance (6MWD)
Time frame: From enrollment until 2 years after the end of intervention.
Functional capacity will be assessed using the 6-minute walk test (6MWT) at baseline and every 6 months. The change in walking distance reflects improvement in functional impairment and exercise tolerance among maintenance hemodialysis (MHD) patients receiving standardized exercise rehabilitation therapy (ERT). Unit of Measure: Meters (m).
Incidence of hospitalization due to cardiovascular events
Time frame: From enrollment until 2 years after the end of intervention.
Hospitalizations caused by cardiovascular events will be recorded, including acute myocardial infarction, other acute coronary syndromes, congestive heart failure requiring hospitalization, and severe arrhythmias (e.g., complete atrioventricular block, cardiac arrest). Data will be used to assess whether ERT reduces cardiovascular morbidity. Incidence will be expressed as the proportion of participants experiencing at least one event during the follow-up period.
Incidence of cerebrovascular events
Time frame: From enrollment until 2 years after the end of intervention.
The occurrence of cerebrovascular events, including intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke (cardioembolic or other etiologies), will be documented and compared between the ERT and control groups. Incidence will be expressed as the proportion of participants experiencing at least one event during the follow-up period.
All-cause mortality
Time frame: From enrollment until 2 years after the end of intervention.
All-cause mortality will be monitored throughout the study to evaluate the long-term safety and prognostic impact of standardized exercise rehabilitation therapy in MHD patients. All-cause mortality will be expressed as the proportion of participants who die from any cause during the follow-up period.
20 secondary outcomes
Change in handgrip strength
Time frame: From enrollment until 2 years after the end of intervention.
Change in lower limb muscle strength assessed by Five Times Sit-to-Stand Test (5STS)
Time frame: From enrollment until 2 years after the end of intervention.
Change in depressive symptoms assessed by the Self-Rating Depression Scale (SDS)
Time frame: From enrollment until 2 years after the end of intervention.
Change in anxiety level assessed by the Self-Rating Anxiety Scale (SAS)
Time frame: From enrollment until 2 years after the end of intervention.
Change in body mass index (BMI)
Time frame: From enrollment until 2 years after the end of intervention.
Change in cognitive function assessed by the Montreal Cognitive Assessment (MoCA)
Time frame: From enrollment until 2 years after the end of intervention.
Change in self-management ability assessed by the Hemodialysis Self-Management Scale
Time frame: From enrollment until 2 years after the end of intervention.
Change in urea reduction ratio (URR)
Time frame: From enrollment until 2 years after the end of intervention.
Change in single-pool Kt/V for urea
Time frame: From enrollment until 2 years after the end of intervention.
Change in hemoglobin concentration
Time frame: From enrollment until 2 years after the end of intervention.
Change in serum ferritin
Time frame: From enrollment until 2 years after the end of intervention.
Change in transferrin saturation (TSAT)
Time frame: From enrollment until 2 years after the end of intervention.
Change in serum calcium
Time frame: From enrollment until 2 years after the end of intervention.
Change in serum phosphate
Time frame: From enrollment until 2 years after the end of intervention.
Change in intact parathyroid hormone (iPTH)
Time frame: From enrollment until 2 years after the end of intervention.
Change in C-reactive protein (CRP)
Time frame: From enrollment until 2 years after the end of intervention.
Change in serum albumin
Time frame: From enrollment until 2 years after the end of intervention.
Change in prealbumin
Time frame: From enrollment until 2 years after the end of intervention.
Change in triglycerides
Time frame: From enrollment until 2 years after the end of intervention.
Change in total cholesterol
Time frame: From enrollment until 2 years after the end of intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2026.
- Individual participant dataSharing planned: Yes
Related trials for End-Stage Renal Disease (ESRD)
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise Rehabilitation Therapy (ERT) in people with End-Stage Renal Disease (ESRD) and Maintenance Hemodialysis (MHD), run by The First People's Hospital of Yunnan at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in 6-minute walk distance (6MWD) (time frame: From enrollment until 2 years after the end of intervention.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2026.